Andrew Bradbury, PhD, MD profile page

Dr. Andrew Bradbury is chief scientific officer of Specifica, which was acquired by IQVIA in 2022. He trained in medicine at the Universities of Oxford and London and received his PhD from the University of Cambridge at the MRC laboratory of molecular biology, under the guidance of Cesar Milstein. He has worked in antibody engineering for over forty years. Driven by Specifica's mission, Andrew is committed to developing therapeutic antibodies with the world’s best antibody selection platform.